Dell and Biosign Technologies Enter into Global Hosting Agreement

Mar 23, 2011, 08:00 ET from Biosign Technologies Inc.

  • Dell to host Biosign's UFIT® and Healthanywhere platforms on a global basis.
  • Enables Biosign to have scalability to meet anticipated subscriber growth

TORONTO, March 23 /PRNewswire/ - Dell (Nasdaq: DELL) ("Dell") and Biosign Technologies Inc. (TSXV: BIO) ("Biosign") have entered into Hosting Agreements whereby Dell will host Biosign's UFIT and Healthanywhere platforms on a global basis. As a single partner for both hardware and support services, Dell will offer Biosign a fully-integrated, end-to-end solution that includes hardware, data center hosting and support.

Biosign's UFIT® is a Service Delivery Platform which talks to medical devices and resides in the Cloud. The on-demand network access to a shared pool of computing resources allows for computational power previous unavailable to end users. The UFIT medical platform is currently only available in Europe, the MENA Region, and Canada.

Biosign's Healthanywhere System is for the collection, transmission, and persistence of medical measurement data and patient care data for the encouragement and tracking of a patient's progress against the goals set between the Healthcare Professional and the patient in the pursuit of providing care for a chronic or post-acute condition and/or to promote patient wellness. Healthanywhere is available worldwide.

"With Dell's technology expertise and global technology capabilities, Biosign will be able to quickly and efficiently scale services to meet anticipated subscriber growth for UFIT and Healthanywhere", stated Peter Tassiopoulos, Chief Executive Officer of Biosign Technologies. "Dell's ability to globally manage data centers, unified networks and architecture made it a natural choice for Biosign to partner with Dell for managing our distributed IT environment."

"We are pleased to provide hosting and technical support to enhance the usability and availability of Biosign's health monitoring technologies", stated Berk Smith, Vice President & General Manager Dell Services Healthcare & Life Sciences. "Dell and Biosign both recognize and seek to leverage the power of the cloud to provide meaningful global healthcare solutions to users around the globe."

About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com

About Dell Inc.
Dell (NASDAQ: DELL) listens to its customers and uses that insight to develop and deliver customized technology solutions that give government, healthcare and educational organizations worldwide the power to do more. Learn more at www.dell.com

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.